论文部分内容阅读
目的:探讨膀胱灌注吡柔比星(THP)预防浅表性膀胱癌术后复发的疗效及安全性。方法:对97例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术(AURBt)或膀胱部分切除术,术后1周开始用THP(30mg/40ml)进行膀胱内定期灌注,每次药物在膀胱内保留30～60分钟,每周1次,连续8次,以后每月1次,连续10次,并随访17～92个月。结果:97例患者均未见全身性药物不良反应,仅9例出现轻微膀胱刺激症状。复发16例,复发率16.49%。结论:膀胱灌注THP预防浅表性膀胱癌术后复发的疗效确切,不良反应小,安全性好,长期疗效待进一步观察。
Objective: To investigate the efficacy and safety of intravesical instillation of pirarubicin (THP) in the prevention of postoperative recurrence of superficial bladder cancer. Methods: Ninety-seven patients with superficial bladder cancer undergoing transurethral resection of the bladder tumor (AURBt) or partial bladder resection were given intravesical instillation of THP (30mg / 40ml) once a week after operation. Each time the drug was administered in the bladder Retained 30 to 60 minutes, once a week for 8 consecutive months, once a month for 10 consecutive times and followed up for 17 to 92 months. Results: No systemic adverse drug reactions were observed in 97 patients, and mild irritation of the bladder was observed in only 9 patients. Recurrence in 16 cases, the recurrence rate was 16.49%. Conclusion: Intravesical instillation of THP in the prevention of postoperative recurrence of superficial bladder cancer has definite curative effect, small adverse reactions, good safety and long-term curative effect to be further observed.